dipyridamole

CLINICAL USE

Antiplatelet agent

DOSE IN NORMAL RENAL FUNCTION

100–200 mg 3 times dailyModified release: 200 mg twice daily

PHARMACOKINETICS

  • Molecular weight                           :504.6
  • %Protein binding                           :97–99
  • %Excreted unchanged in urine     : 1–5
  • Volume of distribution (L/kg)       :1.33–3.53
  • half-life – normal/ESRD (hrs)      :9–12/Unchanged

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Not dialysed. Dose as in normal renal function
  • HD                     :Not dialysed. Dose as in normal renal function
  • HDF/high flux   :Not dialysed. Dose as in normal renal function
  • CAV/VVHD      :Not dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugsAnti-arrhythmics: effects of adenosine enhanced and extendedAnticoagulants: anticoagulant effect of coumarins, phenindione and heparin enhanced

    ADMINISTRATION

    Reconstition

    –

    Route

    Oral

    Rate of Administration

    –

    Comments

    –.

    • Tags:

    Related News

    ffddfd

    Hyperlipidemia